Persistent
hypertriglyceridemia?
Recurrent pancreatitis?

Think Familial Chylomicronemia Syndrome (FCS)

Use this FCS diagnostic algorithm

Hypertriglyceridemia is the third most common cause of acute pancreatitis1

Acute pancreatitis resulting from severe hypertriglyceridemia (HTG) has been associated with longer hospitalization times, increased admission to intensive care units, and higher rates of persistent organ failure compared with acute pancreatitis without HTG.1

Learn more about causes of pancreatitis

Acute pancreatitis and hypertriglyceridaemia may be signs of FCS, a rare genetic disorder4,5

FCS is a genetic disorder of lipid metabolism resulting in severe hypertriglyceridemia >885 mg/dl (>10 mmol/L), and the risk of recurrent and potentially fatal pancreatitis.4,5

Key facts of FCS

Given its rarity and wide range of symptoms FCS can be extremely difficult to recognise

Think of FCS when your patient:4

  • has hypertriglyceridemia
  • has been treated for pancratitis

Use this diagnostic algorithm to identify FCS patients

FCS diagnostic algorithm

Symptoms and complication of FCS

Learn more about the broad spectrum of signs and symptoms that are associated with FCS.

Read more

Diagnosis of FCS

FCS diagnosis is based on a three-step approach: High triglyceride evaluation, Identification of candidates for FCS genetic testing and Genetic test of possible affected genes.

Read more

The importance of early diagnosis in FCS

If you suspect FCS in your patient, use the FCS diagnistic score
to support your clinical suspect.4

Interactive FCS score

References

  1. Nawaz H, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis. Am J Gastroenterol. 2015;110:1497-503.
  2. NCEPOD: Treat the cause. Avaliable at www.ncepod.org.uk/2016ap.html
  3. Valdivielso P, Ramírez-Bueno A, Ewald N. Current knowledge of hypertriglyceridemic pancreatitis. Eur J Intern Med. 2014 Oct;25(8):689-94.
  4. Moulin P, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an ”FCS score”. Atherosclerosis. 2018;275:265-72
  5. Gaudet D, et al. Targeting APOC3 in the Familial Chylomicronemia Syndrome. N Engl J Med. 2014;371:2200-6.

You are leaving the Spotlight FCS website

Please note that this third-party website is not controlled by Spotlight FCS or subject to our privacy policy.

Thank you for visiting Spotlight FCS. We hope you come back again soon.

Open